{"disease":{"id":"enteric-hyperoxaluria","name":"enteric hyperoxaluria"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04909723","title":"Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"Novome Biotechnologies Inc","has_results":false},{"nct_id":"NCT03456830","title":"Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT03847090","title":"Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT05124886","title":"Gut Kidney Axis in Enteric Hyperoxaluria","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT04629170","title":"Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Synlogic","has_results":false},{"nct_id":"NCT05650112","title":"Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Federation Bio Inc.","has_results":false},{"nct_id":"NCT03391804","title":"Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT05377112","title":"Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Synlogic","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}